Clofarabine, Idarubicin, and Cytarabine Combination in Acute Myeloid Leukemia (AML) Induction
- Conditions
- Acute Myeloid Leukemia
- Interventions
- First Posted Date
- 2009-12-03
- Last Posted Date
- 2018-10-09
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 63
- Registration Number
- NCT01025154
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
Safety and Efficacy Study of AS101 to Treat Elderly Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Patients
- First Posted Date
- 2009-11-10
- Last Posted Date
- 2015-02-10
- Lead Sponsor
- BioMAS Ltd
- Target Recruit Count
- 12
- Registration Number
- NCT01010373
- Locations
- 🇮🇱
Sheba Medical Center, Tel Hashomer, Israel
Efficacy Study for AC220 to Treat Acute Myeloid Leukemia (AML)
- Conditions
- Acute Myeloid Leukemia
- Interventions
- Drug: Compound AC220
- First Posted Date
- 2009-10-05
- Last Posted Date
- 2019-12-11
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 333
- Registration Number
- NCT00989261
- Locations
- 🇺🇸
University of California, San Francisco, San Francisco, California, United States
🇺🇸Northwestern Memorial Hospital, Chicago, Illinois, United States
🇺🇸Rush University Medical Center, Chicago, Illinois, United States
Maintenance Therapy in Acute Myeloid Leukemia (AML) Patients
- First Posted Date
- 2009-08-12
- Last Posted Date
- 2015-06-19
- Lead Sponsor
- University Health Network, Toronto
- Target Recruit Count
- 24
- Registration Number
- NCT00957385
- Locations
- 🇨🇦
University Health Network, Princess Margaret Hospital, Toronto, Ontario, Canada
CLAG Gleevec in Relapsed or Refractory Acute Myeloid Leukemia (AML)
- First Posted Date
- 2009-08-10
- Last Posted Date
- 2014-06-27
- Target Recruit Count
- 38
- Registration Number
- NCT00955916
- Locations
- 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
A Phase Ib/IIb, Open-label, Multi-center, Study of Oral Panobinostat Administered With 5-Azacitidine (in Adult Patients With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML).
- Conditions
- Acute Myeloid LeukemiaChronic Myelomonocytic LeukemiaMyelodysplastic Syndromes
- Interventions
- First Posted Date
- 2009-07-27
- Last Posted Date
- 2020-08-04
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 113
- Registration Number
- NCT00946647
- Locations
- 🇺🇸
Georgia Health Sciences University Dept. of MCG, Augusta, Georgia, United States
🇺🇸Goshen Center for Cancer Care IU Cancer Center, Indianapolis, Indiana, United States
🇺🇸University of Kansas Hospital and Medical Center SC - Univ KS, Kansas City, Kansas, United States
Treatment of Acute Myeloid Leukemia (AML) in Adults 50 to 70 Years, Study of Two Anthracyclines and the Interest of Maintenance Treatment With Interleukin 2
- Conditions
- Acute Myeloid Leukemia
- Interventions
- Drug: chemotherapy (Aracytine + Daunorubicin)
- First Posted Date
- 2009-07-02
- Last Posted Date
- 2009-07-02
- Lead Sponsor
- Acute Leukemia French Association
- Target Recruit Count
- 420
- Registration Number
- NCT00931138
- Locations
- 🇫🇷
CH, Versailles, France
🇫🇷Hopital Percy, Clamart, France
🇫🇷CHU, Rouen, France
A Randomized Study of Gemtuzumab Ozogamicin (GO) With Daunorubicine and Cytarabine in Untreated Acute Myeloid Leukemia (AML) Aged of 50-70 Years Old
- Conditions
- Acute Myeloid Leukemia
- Interventions
- Drug: conventional chemotherapy (AraC + Daunorubicin),
- First Posted Date
- 2009-06-25
- Last Posted Date
- 2013-07-11
- Lead Sponsor
- Acute Leukemia French Association
- Target Recruit Count
- 280
- Registration Number
- NCT00927498
- Locations
- 🇫🇷
CH, Valenciennes, France
🇫🇷Hopital Avicenne, Bobigny, France
🇫🇷Hopital Percy, Clamart, France
A Study of Clofarabine in Older Patients With Acute Myeloid Leukemia (AML) for Whom Chemotherapy Is Not Suitable
- First Posted Date
- 2009-06-19
- Last Posted Date
- 2015-04-01
- Lead Sponsor
- Genzyme, a Sanofi Company
- Target Recruit Count
- 69
- Registration Number
- NCT00924443
Azacytidine for the Treatment of Myelodysplastic Syndromes/Acute Myeloid Leukemia (MDS/AML) With High Risk (Chromosome 7 and or Complex) Cytogenetic Abnormalities
- Conditions
- Myelodysplastic SyndromesLeukemia, Myeloid, Acute
- Interventions
- First Posted Date
- 2009-06-08
- Last Posted Date
- 2013-04-24
- Lead Sponsor
- King's College London
- Target Recruit Count
- 40
- Registration Number
- NCT00915785
- Locations
- 🇬🇧
King's College Hospital NHS Foundation Trust, London, United Kingdom